{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:19:59Z","timestamp":1766380799929,"version":"3.48.0"},"reference-count":5,"publisher":"BMJ","issue":"7141","license":[{"start":{"date-parts":[[1998,5,2]],"date-time":"1998-05-02T00:00:00Z","timestamp":894067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1998,5,2]]},"DOI":"10.1136\/bmj.316.7141.1385","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:52:24Z","timestamp":1319745144000},"page":"1385.1","source":"Crossref","is-referenced-by-count":1,"title":["Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII"],"prefix":"10.1136","volume":"316","author":[{"given":"J P","family":"Betts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1998,5,2]]},"reference":[{"key":"2025122121170732000_316.7141.1385.1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/bmj.316.7133.717","article-title":"Blood transfusion risk: protecting against the unknown","volume":"316","author":"Barbara","year":"1998","journal-title":"BMJ"},{"key":"2025122121170732000_316.7141.1385.2","unstructured":"Committee on Proprietary Medicinal Products . Note for guidance: production and quality control of medicinal products derived by recombinant DNA technology. Brussels: CPMP, 1994(III\/3477\/92; revision 1994.)"},{"key":"2025122121170732000_316.7141.1385.3","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1055\/s-0038-1665410","article-title":"A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A","volume":"78","author":"Aygoren-Pursun","year":"1997","journal-title":"Thromb Haemostas"},{"key":"2025122121170732000_316.7141.1385.4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/39057","article-title":"Transmissions to mice indicate that \u2018new variant\u2019 CJD is caused by the BSE agent","volume":"389","author":"Bruce","year":"1997","journal-title":"Nature"},{"key":"2025122121170732000_316.7141.1385.5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2516.1995.tb00118.x","article-title":"Virus safety considerations for recombinant factor VIII (recombinant factor viii, Kogenate)","volume":"1","author":"Arnold","year":"1995","journal-title":"Hemophilia"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.316.7141.1385","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.316.7141.1385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:17:13Z","timestamp":1766380633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.316.7141.1385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5,2]]},"references-count":5,"journal-issue":{"issue":"7141","published-online":{"date-parts":[[1998,5,2]]},"published-print":{"date-parts":[[1998,5,2]]}},"alternative-id":["10.1136\/bmj.316.7141.1385"],"URL":"https:\/\/doi.org\/10.1136\/bmj.316.7141.1385","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1998,5,2]]}}}